202 related articles for article (PubMed ID: 34789774)
1. Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging.
Lu L; Dercle L; Zhao B; Schwartz LH
Nat Commun; 2021 Nov; 12(1):6654. PubMed ID: 34789774
[TBL] [Abstract][Full Text] [Related]
2. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
Hendlisz A; Golfinopoulos V; Garcia C; Covas A; Emonts P; Ameye L; Paesmans M; Deleporte A; Machiels G; Toussaint E; Vanderlinden B; Awada A; Piccart M; Flamen P
Ann Oncol; 2012 Jul; 23(7):1687-93. PubMed ID: 22112970
[TBL] [Abstract][Full Text] [Related]
3. Deep learning-based radiomics predicts response to chemotherapy in colorectal liver metastases.
Wei J; Cheng J; Gu D; Chai F; Hong N; Wang Y; Tian J
Med Phys; 2021 Jan; 48(1):513-522. PubMed ID: 33119899
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review.
Boeckx N; Janssens K; Van Camp G; Rasschaert M; Papadimitriou K; Peeters M; Op de Beeck K
Crit Rev Oncol Hematol; 2018 Jan; 121():1-10. PubMed ID: 29279095
[TBL] [Abstract][Full Text] [Related]
6. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
7. CT-based deep learning model for the prediction of DNA mismatch repair deficient colorectal cancer: a diagnostic study.
Cao W; Hu H; Guo J; Qin Q; Lian Y; Li J; Wu Q; Chen J; Wang X; Deng Y
J Transl Med; 2023 Mar; 21(1):214. PubMed ID: 36949511
[TBL] [Abstract][Full Text] [Related]
8. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
Sahin S; Karatas F
J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
[TBL] [Abstract][Full Text] [Related]
9. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
10. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
Holch JW; Ricard I; Stintzing S; Modest DP; Heinemann V
Eur J Cancer; 2017 Jan; 70():87-98. PubMed ID: 27907852
[TBL] [Abstract][Full Text] [Related]
11. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
12. Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer.
Palmieri LJ; Fihri A; Doat S; Dubreuil O; Manceau G; Karoui M; Wagner M; Lucidarme O; Bachet JB
Eur Radiol; 2019 Jul; 29(7):3871-3880. PubMed ID: 30706121
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A
Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489
[TBL] [Abstract][Full Text] [Related]
15. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
[TBL] [Abstract][Full Text] [Related]
16. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
[No Abstract] [Full Text] [Related]
17. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer.
Byström P; Berglund A; Garske U; Jacobsson H; Sundin A; Nygren P; Frödin JE; Glimelius B
Ann Oncol; 2009 Jun; 20(6):1057-61. PubMed ID: 19164458
[TBL] [Abstract][Full Text] [Related]
18. Special issue "The advance of solid tumor research in China": Prognosis prediction for stage II colorectal cancer by fusing computed tomography radiomics and deep-learning features of primary lesions and peripheral lymph nodes.
Li M; Gong J; Bao Y; Huang D; Peng J; Tong T
Int J Cancer; 2023 Jan; 152(1):31-41. PubMed ID: 35484979
[TBL] [Abstract][Full Text] [Related]
19. Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
Moehler M; Thomaidis T; Zeifri C; Barhoom T; Marquardt J; Ploch P; Schattenberg J; Maderer A; Schimanski CC; Weinmann A; Woerns MA; Kranich AL; Warnecke JM; Galle PR
J Cancer Res Clin Oncol; 2015 Mar; 141(3):515-22. PubMed ID: 25230900
[TBL] [Abstract][Full Text] [Related]
20. Deep learning radio-clinical signatures for predicting neoadjuvant chemotherapy response and prognosis from pretreatment CT images of locally advanced gastric cancer patients.
Hu C; Chen W; Li F; Zhang Y; Yu P; Yang L; Huang L; Sun J; Chen S; Shi C; Sun Y; Ye Z; Yuan L; Chen J; Wei Q; Xu J; Xu H; Tong Y; Bao Z; Huang C; Li Y; Du Y; Xu Z; Cheng X
Int J Surg; 2023 Jul; 109(7):1980-1992. PubMed ID: 37132183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
